Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 2 75 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus EPANOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 2 75 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus EPANOVA.
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs EPANOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 2.75/10 is a parenteral nutrition solution providing amino acids, dextrose, electrolytes, and calcium. Amino acids serve as substrates for protein synthesis, dextrose provides caloric energy, and electrolytes maintain fluid and electrolyte balance.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Intravenous infusion. Adult dose: 1-2 L per day, administered at a rate not exceeding 100 mL/hour initially, then adjusted based on metabolic and fluid requirements. Each liter contains amino acids 27.5 g, dextrose 100 g, and electrolytes including calcium.
4 g orally once daily as 4 capsules of 1 g each with food.
None Documented
None Documented
Not applicable as a fixed combination product; individual components have half-lives: amino acids ~0.5-2 h, dextrose ~2-4 h, electrolytes vary (e.g., calcium ~2-4 h).
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Renal excretion of infused amino acids and electrolytes; glucose is metabolized to CO2 and water; 100% of water and electrolytes excreted renally.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution